Lantern Pharma Inc. 8-K

What Happened

• Lantern Pharma Inc. (LTRN) filed a Current Report on Form 8-K (Regulation FD Disclosure, Item 7.01) on January 23, 2026 reporting that on January 22, 2026 the company hosted an event to discuss and demonstrate, in a live environment, its initial AI tools and multi-agentic system focused on rare cancers.
• The presentation used at the event is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: January 23, 2026 (Form 8-K, Item 7.01 – Regulation FD Disclosure).
• Event date: January 22, 2026 — company-hosted demonstration of AI tools and a multi-agentic system.
• Exhibit provided: Presentation is included as Exhibit 99.1 to the Form 8-K.
• Focus area: AI tools and multi-agent system aimed at rare cancers; disclosed publicly under Regulation FD.

Why It Matters

• This filing publicly documents Lantern’s progress in deploying AI-driven tools and a multi-agent system for rare-cancer work, which is a strategic, non-financial development investors can review via the attached presentation.
• Because the disclosure was made under Regulation FD, the information was shared broadly and simultaneously to avoid selective disclosure.
• The 8-K does not include financial results, clinical outcomes, or material agreements — investors should review Exhibit 99.1 for specifics on the technology and look for future disclosures for clinical or commercial milestones.